The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R/R DLBCL

In this presentation, Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses the Phase III STARGLO trial (NCT04408638), which compared the safety and efficacy of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after at least one prior line of therapy. This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.